Table 1 Availability of the asthma-COPD drugs and diagnostic tests in private and public hospitals and private pharmacies (n = 130)
Availability (%) | |||||
|---|---|---|---|---|---|
A: Selected medicines (N = 10 classes and 2 types of spacers) | Availability (%) in all study sites (N = 130) | Public hospitals (N = 23) | Private hospitals (N = 22) | Private pharmacies (N = 85) | P value |
Inhaled LAMA monotherapies | 0.0 | 0.0 | 0.0 | 0.0 | NA |
Inhaled LABA and LAMA combinations | 0.0 | 0.0 | 0.0 | 0.0 | NA |
Inhaled LABA monotherapies | 10.0 | 0.0 | 0.0 | 15.3 | 0.022 |
Inhaled SABA and SAMA combinations. | 10.8 | 0.0 | 4.6 | 15.3 | 0.065 |
Inhaled SAMA monotherapy | 12.3 | 0.0 | 0.0 | 18.8 | 0.008 |
Oral methylxanthines | 16.9 | 4.0 | 18.2 | 20.0 | 0.203 |
Adult spacer devices | 18.5 | 0.0 | 0.0 | 28.2 | <0.001 |
Paediatric spacer devices | 19.2 | 0.0 | 4.6 | 28.2 | 0.002 |
ICS monotherapies | 45.4 | 4.0 | 50.0 | 55.3 | <0.001 |
Inhaled LABA- ICS combinations | 46.9 | 0.0 | 40.9 | 61.2 | <0.001 |
Oral LTRA | 60.8 | 0.0 | 59.1 | 76.7 | <0.001 |
Inhaled SABA monotherapy | 75.0 | 26.1 | 77.3 | 88.2 | <0.001 |
B: Diagnostic/monitoring tests | |||||
Peak flow-metry | 6.7 | 8.7 | 4.6 | NA | 0.577 |
Spirometry | 24.4 | 34.8 | 13.6 | NA | 0.099 |